The latest analysis used blood-protein data collected during a Phase IIa trial of the drug. Researchers examined 2,841 proteins and applied six independently developed aging models to estimate changes in participants' biological age.
Across the different models, patients treated with rentosertib generally showed lower predicted biological ages than those receiving placebo. The largest reported effect appeared at week four among participants taking 30 milligrams twice a day, with estimated reductions of roughly three to four years and as much as six years under one of the aging clocks.
The results do not establish that rentosertib slows human aging itself. Aging clocks attempt to estimate biological age from measurable changes in the body, but there is no universally accepted method for translating those scores into a definitive measure of aging or lifespan.
Researchers also examined lung function, an important measure in patients with IPF. Earlier Phase IIa results published in Nature Medicine showed that participants receiving 60 milligrams once daily had an average 98.4-milliliter improvement in forced vital capacity, compared with a 20.3-milliliter decline in the placebo group.
The dose associated with the strongest biological-age signal was different from the dose showing the largest improvement in lung function. Researchers said that distinction suggests the changes detected by the aging clocks may not simply reflect improvements in patients' respiratory disease.
The team also compared protein patterns from the trial with 55,319 profiles from the UK Biobank. According to the study, rentosertib shifted some protein-expression patterns in the opposite direction from changes typically associated with aging.
Insilico developed the drug after identifying TNIK as relevant to both fibrosis and aging biology. The company said the target scored highly across six hallmarks of aging before being selected for further development. Rentosertib then progressed from target identification to selection as a preclinical candidate in about 18 months.
The research was conducted with scientists from institutions including Harvard Medical School, Stanford University, the Broad Institute, RWTH Aachen University, Peking University and Westlake University.
The study remains an early clinical signal rather than evidence that rentosertib can extend human lifespan. The findings instead provide an initial test of whether biological-aging measurements can be incorporated into conventional drug trials alongside disease-specific outcomes.
Insilico has made the trial data available through the China National Center for Bioinformation and released the underlying analysis pipeline as an open-source Python library. The company and its collaborators are proposing that aging and cellular-senescence biomarkers be collected as exploratory endpoints in future disease-focused studies, potentially giving researchers another way to identify drugs with possible effects on aging biology.
This analysis is based on reporting from Gizmodo.
Image courtesy of Unsplash.
This article was generated with AI assistance and reviewed for accuracy and quality.
